ACCENT PHARMA, JAMMU
QUALITY CONTROL DEPARTMENT
Finished Product Certificate of Analysis
(Under Drugs & Cosmetics Act 1940 & rules made there under)

PRODUCT:	**Minisprin 75**
GENERIC NAME :	**ASPIRIN GASTRO – RESISTANT TABLETS IP 75MG**
A.R. No.: AP/02/FP/26/473	Batch Size: 30.0 Lac.
Batch No.: AMR26006	Date of Sampling: 23/10/2026
Mfg. Date: OCT.2026	Quantity Sampled: 14 Tablets
Exp. Date: SEP.2028	Date of Analysis: 23/10/2026
Manufactured for: American Remedies	Date of Release : 29/10/2026
STP No.: AP/02/FP/M002/01	Mother B.No.of Aspirin Gastro-resistant tablet used:AGA26005

Sr. No.	Test	Limit	Observation
1.	Description	**Bulk:-**White coloured,circular shaped, slightly biconvex plain surface gastro resistant tablet.	**Bulk:-**White coloured,circular shaped, slightly biconvex plain surface gastro resistant tablet.
		FG Stage:-Gastro resistant tablet packed in plain printed Aluminum foil with 1X14's tablets per strip.	**FG Stage:-**Gastro resistant tablet packed in plain printed Aluminum foil with 1X14's tablets per strip
2.	Identification	**A(By HPLC)** Retention time of the major peak of sample preparation corresponds to that of standard as obtained in the assay. **B(BY IR)** The infra red spectrum of a KBr dispersion of it, previously dried exhibits maxima only at the same wavelengths as that of similar preparation of working standard.	Complies
3.	Average Weight of tablet	112.00mg ± 5% (106.4mg - 117.6 mg)	110.50mg
4.	Uniformity of weight	Average weight ± 10.0%	+2.67% -3.03%
5.	Thickness of tablets	3.2 ± 0.2mm (3.0mm-3.4 mm)	Min.3.04mm. Max.3.15mm.
6.	Diameter of tablets	6.0 ± 0.2mm (5.8mm-6.2mm)	Min.6.05mm. Max.6.20mm.
7.	Hardness of tablets	NLT 30 Newton (N)	Min.90.56N Max.106.76N
8.	Disintegration Test	**In Acid (0.1M HCl):** No tablet show any evidence of disintegration, cracking or softening (apart from fragments of coating) or cracks for 2 hour at 37^0 C ±2^0 C	complies
		In Buffer (Phosphate buffer PH 6.8): Not more than 60 minutes at 37^0 C ±2^0 C	12 min. 25 Sec.
9.	**Dissolution: (By UV)** **For Aspirin** a) In 0.1M HCl acid for 2 hours	Not more than 10.0%	Avg.1.87% Max.2.43% Min.0.75%
	b) In mix phosphate buffer pH 6.8 for 45 minutes.	Not less than 70.0% (Q)	Avg.102.24% Max.104.56% Min.99.23%
10.	Salicylic acid (By HPLC)	Not more than 3.0%	0.18%

APPROVED

	Prepared By	Checked By	Approved By
Name	Rohit Jaswal	Ashwani Jamwal	Rinku SHARMA
Sign.	(R)		
Date	29/10/2026	29/10/2026	29/10/2026

ACCENT PHARMA, JAMMU
QUALITY CONTROL DEPARTMENT
Finished Product Certificate of Analysis
(Under Drugs & Cosmetics Act 1940 & rules made there under)

PRODUCT:	**Minisprin 75**
GENERIC NAME :	**ASPIRIN GASTRO – RESISTANT TABLETS IP 75MG**
A.R. No.: AP/02/FP/26/473	Batch Size: 30.0 Lac.
Batch No.: AMR26006	Date of Sampling: 23/10/2026
Mfg. Date: OCT.2026	Quantity Sampled: 14 Tablets
Exp. Date: SEP.2028	Date of Analysis: 23/10/2026
Manufactured for: American Remedies	Date of Release : 29/10/2026
STP No.: AP/02/FP/M002/01	Mother B.No.of Aspirin Gastro-resistant tablet used:AGA26005

11.	**Assay: (By HPLC)** Gastro resistant tablet contains:		
	For Aspirin IP 75mg	(95.0%-105% of label claim)	76.182mg 101.58%
12.	**Uniformity of content(By weight variation)** For Aspirin	Acceptance Value NMT 15	5.33 (Aspirin)
13.	**Additional test***		
	Microbial limit Test: Total bacterial count Total fungal count E coli Salmonella Staphylococcus aureus Pseudomonas aeruginosa	Not more than 1000 CFU/gm Not more than 100 CFU/gm Absent/gm Absent/10gm Absent/gm Absent/gm	35/cfu gm <10/cfu gm Absent Absent Absent Absent

Remarks: In the opinion of the undersigned, the sample referred to above is of Standard Quality/~~Not of Standard Quality~~ as defined in the Drugs & Cosmetics Act 1940 & Rules made there under as per Specification No.: **AP/02/SPC/FP/M002/01.**

APPROVED

	Prepared By	Checked By	Approved By
Name	Rohit Jasrotia	Ashwani Kumar	RINKU SHARMA
Sign.			
Date	29/10/2026	29/10/2026	29/10/2026